SCHEMBL13601281

SCHEMBL13601281

Cc1nc(NCc2cccnc2)c2nc[nH]c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
CYP1A2 P05177 4/20 0.46
CYP3A4 P08684 4/20 0.46
CYP2C19 P33261 4/20 0.46
CYP2D6 P10635 3/20 0.46
HSD17B10 Q99714 3/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 3/20 0.44
PKM P14618 1/20 0.44
USP1 O94782 1/20 0.44
WDR48 Q8TAF3 1/20 0.44
PDE10A Q9Y233 1/20 0.44
LTA4H P09960 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8009110 0.85 CYP3A4 (0.50) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3852234 0.85 KDM4C (0.49) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3302002 0.85 MEN1 (0.47) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL16145955 0.81 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10
SCHEMBL13906518 0.81 TLR7 (0.43) ALDH1A1MAPK1KDM4EPKMPOLB
SCHEMBL17017484 0.81 KDM4C (0.59) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL30850661 0.81 KDM4C (0.59) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL16147023 0.80 PRMT1 (0.52) ALDH1A1CYP3A4MAPK1SMN1; SMN2KDM4E
SCHEMBL16146133 0.79 TMIGD3 (0.56) MAPK1KMT2A
SCHEMBL16146671 0.79 AURKA (0.54) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846696-B2 Purine derivatives CYCLACEL LIMITED (GB) 2014-09-30 US disclosed
US-20090325983-A1 NEW PURINE DERIVATIVES CYCLACEL LIMITED (GB) 2009-12-31 US disclosed
US-7582642-B2 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors CYCLACEL LIMITED (GB) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325983-A1 NEW PURINE DERIVATIVES C5, CYC1, CCNH ALDH1A1 1573/4885PDE4A 1465/4885PDE4B 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.